» Articles » PMID: 15667967

Prognostic Significance of Parapharyngeal Space Venous Plexus and Marrow Involvement: Potential Landmarks of Dissemination for Stage I-III Nasopharyngeal Carcinoma

Overview
Specialties Oncology
Radiology
Date 2005 Jan 26
PMID 15667967
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine whether the parapharyngeal space venous plexus and marrow of the skull base bones are anatomic landmarks of the potential routes for the spread of disease for Stage I-III (American Joint Commission on Cancer 1997 staging system) nasopharyngeal carcinoma (NPC).

Methods And Materials: A total of 364 patients with NPC were enrolled in this study. The selection criteria were Stage I-III disease and primary radiotherapy at our hospital between 1990 and 2001. All patients had undergone MRI to evaluate the head-and-neck tumors. Patients who had undergone inadequate radiotherapy at a dose of <60 Gy and/or preradiotherapy chemotherapy before the imaging evaluation were excluded from the study.

Results: Of the 364 patients treated between 1990 and 2001, 163 (44.8%) had low-risk Stage I-III NPC (without parapharyngeal space extension or T3 disease). The 5-year distant metastasis-free survival rate, with and without adjuvant chemotherapy, was 97% and 96%, respectively. The remaining 201 patients had Stage II-III with parapharyngeal space extension or T3 disease. Their 5-year recurrence-free survival rate, with and without adjuvant chemotherapy, was 76.8% and 53.2% (p = 0.01), respectively.

Conclusion: Our findings suggest that the risk of distant metastasis in Stage I-III NPC patients without parapharyngeal space extension or T3 disease is extremely low. Invasion into the parapharyngeal space venous plexus and marrow of the skull base bones is associated with distant metastasis, and involvement of these anatomic sites is considered a potential route for hematogenous disease spread in patients with Stage I-III NPC.

Citing Articles

Survival among subgroups of patients with stage II nasopharyngeal carcinoma.

Huang S, Su D Sci Rep. 2022; 12(1):7007.

PMID: 35488053 PMC: 9054756. DOI: 10.1038/s41598-022-11145-4.


Staging of T2 and T3 nasopharyngeal carcinoma: Proposed modifications for improving the current AJCC staging system.

Cui C, Li H, Ma H, Dong A, Xie F, Liang S Cancer Med. 2020; 9(20):7572-7579.

PMID: 32871059 PMC: 7571804. DOI: 10.1002/cam4.3328.


Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation.

Peng L, Yang Y, Guo R, Mao Y, Xu C, Chen Y Cancer Med. 2018; 7(12):5988-5998.

PMID: 30378277 PMC: 6308091. DOI: 10.1002/cam4.1858.


Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy.

Pan X, Huang S, Chen K, Jiang Y, Ma J, Qu S Oncotarget. 2017; 8(8):14029-14038.

PMID: 28152511 PMC: 5355159. DOI: 10.18632/oncotarget.14932.


Intensity-modulated radiotherapy controls nasopharyngeal carcinoma distant metastasis and improves survival of patients.

Chen X, Lei H, Liang Z, Li L, Qu S, Zhu X Springerplus. 2016; 5(1):1459.

PMID: 27652034 PMC: 5007237. DOI: 10.1186/s40064-016-3117-1.